Next 10 |
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...
MIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, would like to remi...
MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...
2024-05-30 17:29:56 ET The Russell 3000 index will have a new look on June 28, after the market closes, when 225 securities will be added and 144 securities will be deleted as part of the annual reconstitution. Following are some notable consumer staples companies which will be ...
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced tha...
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced Ste...
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced tha...
2024-05-08 06:33:25 ET More on Veru Veru Inc. (VERU) Q1 2024 Earnings Call Transcript Veru Q2 2024 Earnings Preview Veru gets Nasdaq notice related to delayed quarterly report on form 10-Q Seeking Alpha’s Quant Rating on Veru Historical earning...
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy ® * ) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical,...
2024-05-07 12:06:40 ET More on Veru Veru Inc. (VERU) Q1 2024 Earnings Call Transcript Veru gets Nasdaq notice related to delayed quarterly report on form 10-Q Seeking Alpha’s Quant Rating on Veru Historical earnings data for Veru Financial info...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...
MIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, would like to remi...
MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced th...